Firms claim alliance will guarantee optimized processes for purification and synthesis.
Combining gene therapy and protein engineering to "tune" calcium receptors appears to improve heart function in an animal model of heart disease.
Torque, a developer of T-cell cancer therapeutics produced through its Deep-Priming™ technology platform, says its Slipstream™ process for making Deep-Primed T-Cells is designed to deliver substantially greater efficiency over current cell therapy manufacturing through savings in cost, time, and labor.
Firm will build VLP vaccine manufacturing plant and will also develop flu vaccines for other emerging markets.
Purolite and Codexis are collaborating to develop and market immobilized enzymes for the pharmaceutical industry.
The companies ink a commercial license and supply agreement replacing an earlier research agreement that allowed Amgen to evaluate AMG 330 with Captisol in preclinical and early clinical studies
KAHR to start clinical trials with RA candidate in 2010. The trans signal converter proteins are a therapeutic with two functional sides.
Facility increases capacity from 1,000 to 8,000 L and uses single-use technology.
SCB-808, a prefilled syringe formulation Enbrelâ (etanercept) biosimilar candidate, will be the first therapeutic product to be produced at Clover’s facility using FlexFactory
Firms aim to develop GenVec’s gene-based therapy for restoring hearing and balance.
Please wait while you are redirected to the right page...